Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
Schilling
P J
PJ
Vadhan-Raj
S
S
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001088:Arabinonucleotides / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000209:etiology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000209:etiology*; D011020:Pneumonia, Pneumocystis / Q000209:etiology*; D001084:Vidarabine Phosphate / Q000009:adverse effects* / Q000031:analogs & derivatives
D000964:Antimetabolites, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate